Dear Friend of LuMind IDSC, Recently, I spoke with a family whose newborn baby had…
adminJanuary 18, 2023
Our Impact Report 2022 highlights our accomplishments as an organization during a remarkable year. 2022 saw Down syndrome research receive unprecedented attention from policymakers, the media, and the pharmaceutical and life sciences industries. Click here to read our full report!
https://lumindidsc.org/wp-content/uploads/2023/01/Impact_Report_2022_FINAL_Digital.pdf
At an Alzheimer’s disease research conference last week, new clinical trial data was presented for…
Kate O’NeillDecember 5, 2022
LuMind IDSC and the Down Syndrome Clinical Trials Network are pleased to announce the launch…
Kate O’NeillNovember 16, 2022
Eisai, a Japanese pharmaceutical company, and its partner Biogen, a Massachusetts-based biotechnology company, recently announced…
Kate O’NeillNovember 1, 2022
In a recent report, the National Task Group on Intellectual Disabilities and Dementia Practices (NTG)…
Kate O’NeillOctober 17, 2022
Learn more about Down syndrome research Learn more about resources for families Learn more about…
Kate O’NeillOctober 3, 2022
September 16, 2022 Research recently published in the journal Science (Manfredi-Lozano et al., Science 377,…
Kate O’NeillSeptember 16, 2022
In July 2022, John Cronin and his parents invited LuMind IDSC to follow their family…
Kate O’NeillSeptember 7, 2022